@sigven sigven released this May 14, 2018 · 104 commits to master since this release

Assets 2
v0.6.2.1

0.6.2.1 release

@sigven sigven released this May 9, 2018 · 109 commits to master since this release

Assets 2

Fixed various bugs reported by users

  • grch38 support for mutational signature analysis
  • copy number annotation
  • filtering stats shown in tumor-only option

0.6.2 also comes with updated data bundle.

Thanks to valuable contributions/testing by @vladsaveliev, @zacshi, @shukwong, @patidarr

Pre-release

@sigven sigven released this May 2, 2018 · 114 commits to master since this release

Assets 2
  • Fixed reported bugs in tier assignment of variants
Pre-release

@sigven sigven released this Apr 25, 2018 · 128 commits to master since this release

Assets 2
  • Updated data sources
  • Enabling specification of tumor type of input sample
  • New tier system for classification of variants (ACMG-like)
  • VCF validation can be turned off
  • Tumor DP/AF presets
  • JSON dump of report content
  • GRCh38 support
  • Runs under Python3

@sigven sigven released this Nov 29, 2017 · 137 commits to master since this release

Assets 2

Corrects a bug with propagation of default options

@sigven sigven released this Nov 23, 2017 · 140 commits to master since this release

Assets 2
0.5.2 release
Pre-release

@sigven sigven released this Nov 21, 2017 · 142 commits to master since this release

Assets 2
0.5.1.2

vep fail option
Pre-release

@sigven sigven released this Nov 18, 2017 · 145 commits to master since this release

Assets 2
  • fixed a bug in new ClinVar VCF
  • added VEP option --failed
Pre-release

@sigven sigven released this Nov 15, 2017 · 152 commits to master since this release

Assets 2
  • fixed a bug with VCF validation
Pre-release

@sigven sigven released this Nov 14, 2017 · 156 commits to master since this release

Assets 2
  • Updated version of VEP (v90)
  • Updated versions of ClinVar, Uniprot KB, CIViC, CBMDB
  • Removal of ExAC (replaced by gnomAD), removal of COSMIC due to licensing restrictions
  • Users can analyze samples run without matching control (i.e. tumor-only)
  • PCGR pipeline is now configured through a TOML-based configuration file
  • Bug fixes / general speed improvements